Research and Development Focused on “Lifelong Health”
First written in FY2016. 13 of 34 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥2,064 million. The segment breakdown, including the allocation to each segment of R&D expenses that cannot be classified into a specific segment, was ¥465 million for the Marine Resources Business, ¥1,274 million for the Food Distribution Business, ¥605 million for the Processed Foods Business, and a negative ¥279 million in unallocated corporate expenses.」
R&D expenses increased from ¥1,843 million in the previous fiscal year to ¥2,064 million. The company is advancing R&D in food tech, marine tech and biotech, as well as in the digital field. - FY2026-H1Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the interim consolidated fiscal year was ¥914 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated fiscal year.」
The company disclosed R&D expenses of ¥914 million and stated that there were no material changes in the status of R&D activities. - FY2025AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥1,843 million. The segment breakdown, including the allocation to each segment of R&D expenses that cannot be classified into a specific segment, was ¥680 million for the Marine Resources Business, ¥612 million for the Food Distribution Business, ¥329 million for the Processed Foods Business, ¥50 million for Other, and ¥169 million in unallocated corporate expenses.」
R&D expenses were ¥1,843 million, and the company disclosed the allocations to marine resources, food distribution and processed foods, among other areas. - FY2025-H1Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the interim consolidated fiscal year was ¥879 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated fiscal year.」
The company updated R&D expenses for the interim consolidated fiscal year to ¥879 million and stated that there were no material changes in the status of R&D activities. - FY2024-Q3Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first nine months of the current consolidated fiscal year was ¥1,233 million.」
The company updated R&D expenses for the first nine months to ¥1,233 million and stated that there were no material changes in the status of R&D activities. - FY2024-Q2Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first half of the current consolidated fiscal year was ¥861 million. There were no material changes in the status of the Group's R&D activities during the first half of the current consolidated fiscal year.」
The company updated first-half R&D expenses to ¥861 million and reaffirmed that there were no material changes in the status of R&D activities. - FY2024-Q1Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first quarter of the current consolidated fiscal year was ¥439 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
The company updated first-quarter R&D expenses to ¥439 million and reaffirmed that there were no material changes in R&D activities. - FY2023AdvancedAnnual report
「In particular, to efficiently advance the "Innovation Ecosystem" set out in the medium-term management plan, the company focused on areas including ① food tech, ② marine tech and ③ biotech. Total R&D expenses for the consolidated fiscal year were ¥1,652 million.」
R&D activities were organized under the Innovation Ecosystem into food tech, marine tech and biotech, with annual R&D expenses of ¥1,652 million recorded. - FY2023-Q3Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first nine months of the current consolidated fiscal year was ¥1,217 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
The company updated R&D expenses for the first nine months to ¥1,217 million and stated that there were no material changes in the status of R&D activities. - FY2023-Q2Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first half of the current consolidated fiscal year was ¥777 million.」
The company updated first-half R&D expenses to ¥777 million and stated that there were no material changes in the status of R&D activities. - FY2023-Q1Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first quarter of the current consolidated fiscal year was ¥374 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
The company disclosed first-quarter R&D expenses of ¥374 million and reaffirmed that there were no material changes in the status of R&D activities. - FY2022AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥1,647 million. The segment breakdown, including the allocation to each segment of R&D expenses that cannot be classified into a specific segment, was ¥1,064 million for the Marine Resources Business, ¥596 million for the Processing Business, ¥20 million for the Logistics Business, and a negative ¥34 million in unallocated corporate expenses.」
The company disclosed R&D expenses of ¥1,647 million and specified the allocations to marine resources, processing and logistics. The research focus has also expanded to include low-fishmeal and low-fish-oil feed, land-based aquaculture, breeding of fully farmed fish, and the use of AI and IoT. - FY2022-Q3Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first nine months of the current consolidated fiscal year was ¥1,133 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the current consolidated fiscal year.」
The company disclosed R&D expenses of ¥1,133 million for the first nine months and reaffirmed that there were no material changes in R&D activities. - FY2022-Q2Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first half of the current consolidated fiscal year was ¥752 million. There were no material changes in the status of the Group's R&D activities during the first half of the current consolidated fiscal year.」
The company disclosed R&D expenses of ¥752 million for the first half and reaffirmed that there were no material changes in R&D activities. - FY2022-Q1Update to R&D ExpensesAnnual report
「The total amount of R&D activities across the Group during the first quarter of the current consolidated fiscal year was ¥407 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated fiscal year.」
The company disclosed first-quarter R&D expenses of ¥407 million and stated that there were no material changes in R&D activities. - FY2021AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥1,556 million. The segment breakdown, including the allocation to each segment of R&D expenses that cannot be classified into a specific segment, was ¥563 million for the Fisheries and Aquaculture Business, ¥391 million for the Trading Business, ¥189 million for the Overseas Business, ¥560 million for the Processing Business, ¥17 million for the Logistics Business, and a negative ¥165 million in unallocated corporate expenses.」
R&D expenses were ¥1,556 million, up 38.6% from ¥1,123 million in the previous fiscal year. The research focus has also become more specific in areas including aquaculture technology, functional materials and food safety. - FY2021-Q3Update to R&D ExpensesAnnual report
「The Group’s total research and development expenses for the nine-month period ended September 30 were ¥1,169 million. There was no material change in the status of the Group’s research and development activities during the nine-month period ended September 30.」
R&D expenses were ¥1,169 million, and the filing states that there were no material changes in the status of R&D activities. - FY2021-Q2Update to R&D ExpensesAnnual report
「The Group’s total research and development expenses for the six-month period ended June 30 were ¥860 million. There was no material change in the status of the Group’s research and development activities during the six-month period ended June 30.」
The company disclosed research and development expenses of ¥860 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2021-Q1RestatedAnnual report
「The Group’s total research and development expenses for the three-month period ended June 30 were ¥401 million. There was no material change in the status of the Group’s research and development activities during the three-month period ended June 30.」
The company disclosed research and development expenses of ¥401 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2020-Q3RestatedAnnual report
「The Group’s total research and development expenses for the nine-month period ended September 30 were ¥795 million. There was no material change in the status of the Group’s research and development activities during the nine-month period ended September 30.」
The company disclosed research and development expenses of ¥795 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2020-Q2RestatedAnnual report
「The Group’s total research and development expenses for the six-month period ended June 30 were ¥509 million. There was no material change in the status of the Group’s research and development activities during the six-month period ended June 30.」
The company disclosed research and development expenses of ¥509 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2020-Q1RestatedAnnual report
「Group-wide R&D expenses for the three-month period ended the first quarter were ¥260 million. There was no material change in the status of the Group's R&D activities during the three-month period ended the first quarter.」
The company disclosed research and development expenses of ¥260 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2019-Q3RestatedAnnual report
「The Group’s total research and development expenses for the nine-month period ended September 30 were ¥727 million. There was no material change in the status of the Group’s research and development activities during the nine-month period ended September 30.」
The company disclosed research and development expenses of ¥727 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2019-Q2RestatedAnnual report
「The Group’s total research and development expenses for the six-month period ended June 30 were ¥483 million. There was no material change in the status of the Group’s research and development activities during the six-month period ended June 30.」
The company disclosed research and development expenses of ¥483 million and reaffirmed that there has been no material change in the status of its research and development activities. - FY2019-Q1RestatedAnnual report
「R&D expenditure for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥242 million. There were no material changes in the status of the Group’s R&D activities during the period.」
The company disclosed research and development expenses of ¥242 million and reaffirmed that there has been no material change in the direction of its research and development activities. - FY2018AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥841 million. Including allocations to each segment of research and development expenses that cannot be classified into a specific segment, the breakdown by segment was ¥85 million for the Fisheries and Aquaculture business, ¥267 million for the Trading business, ¥146 million for the Overseas business, ¥349 million for the Processing business, ¥12 million for the Logistics business, and a ¥20 million difference in the allocation of company-wide expenses.」
Research and development expenses increased to ¥841 million from ¥798 million in the previous fiscal year. - FY2018-Q3RestatedAnnual report
「The Group’s total research and development expenses for the nine-month period ended September 30 were ¥594 million. There was no material change in the status of the Group’s research and development activities during the nine-month period ended September 30.」
The company disclosed research and development expenses of ¥594 million and reaffirmed that there has been no material change in its research and development activities. - FY2018-Q2RestatedAnnual report
「The Group’s total research and development expenses for the six-month period ended June 30 were ¥391 million. There was no material change in the status of the Group’s research and development activities during the six-month period ended June 30.」
The company disclosed research and development expenses of ¥391 million and reaffirmed that there has been no material change in its research and development activities. - FY2018-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group during the first quarter of the current consolidated cumulative period was ¥198 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company disclosed research and development expenses of ¥198 million and reaffirmed that there has been no material change in its research and development activities. - FY2017AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year were ¥798 million. Including allocations to each segment of research and development expenses that cannot be classified into a specific segment, the breakdown by segment was ¥62 million for the Fisheries and Aquaculture business, ¥247 million for the Trading business, ¥139 million for the Overseas business, ¥377 million for the Processing business, ¥11 million for the Logistics business, and a ¥39 million difference in the allocation of company-wide expenses.」
The company incurred ¥798 million in research and development expenses and disclosed the amount invested in research and development by segment. - FY2017-Q3RestatedAnnual report
「The Group's research and development expenditure for the nine months ended 31 December was ¥564 million. There were no material changes in the status of the Group's research and development activities during the nine months ended 31 December.」
The company explicitly states that there has been no material change in its research and development activities and reports cumulative research and development expenses of ¥564 million. - FY2017-Q2RestatedAnnual report
「There were no material changes in the status of the Group's research and development activities during the cumulative second quarter.」
The company explicitly states that there has been no material change in the direction of its research and development activities. - FY2017-Q1RestatedAnnual report
「There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company explicitly states that there has been no material change in the direction of its research and development activities. - FY2016First statedAnnual report
「We are pursuing research activities under the slogan “Lifelong Health,” with the aim of accumulating research and development capabilities and technical expertise to propose products that contribute to our customers’ health.」
Proposing products that contribute to health is the basic direction of the company’s research and development.